Head of preclinical development
ExeVir Bio, Belgium
Disclosure(s): ExeVir Bio: Employee, Patent inventor
Florence Herschke, PhD, is currently Head of Preclinical Development at ExeVir Bio, a small biotech harnesting the power of heavy-chain only (VHH) antibodies to fight SARS-CoV-2, Dengue and other infectious diseases.
She is a passionate virologist, immunologist and drug discoverer, working with large & small molecules or gene therapy modalities. She is always looking for ways to help ID patients & increase the knowledge around viruses. Prior to ExeVir, she was for 16 years at Johnson & Johnson/ Tibotec, leading the discovery and early clinical development of direct antivirals & host immune modulators against Hepatitis B & C, Influenza, RSV and SARS-CoV-2. She was trained at the Ecole Normale Supérieure de Paris-Saclay and holds a PhD & a teaching degree from the University of Lyon, France.